Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing?

In this article we will dive into HAEMONETICS CORP/MASS (NYSE:HAE) as a possible candidate for quality investing. Investors should always do their own research, but we noticed HAEMONETICS CORP/MASS showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Some of the quality metrics of NYSE:HAE highlighted

• HAEMONETICS CORP/MASS has demonstrated significant revenue growth over the past 5 years, with a 5.27% increase. This underscores the company's ability to adapt to market dynamics and capitalize on growth opportunities.
• HAEMONETICS CORP/MASS demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 19.62% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
• With a Debt/Free Cash Flow Ratio of 4.35, HAEMONETICS CORP/MASS exhibits solid financial health and responsible debt management practices. This ratio indicates the company's ability to generate ample free cash flow to meet its debt obligations and pursue growth opportunities.
• With a favorable Profit Quality (5-year) ratio of 124.0%, HAEMONETICS CORP/MASS showcases its ability to consistently deliver high-quality profits. This metric signifies the company's financial strength and its capacity to generate sustainable earnings over an extended period.
• HAEMONETICS CORP/MASS has consistently achieved strong EBIT growth over the past 5 years, with a 10.96% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
• HAEMONETICS CORP/MASS demonstrates a remarkable trend where its EBIT 5-year growth exceeds its Revenue 5-year growth. This indicates the company's ability to enhance its profitability through improved cost control and operational efficiency.

How does the complete fundamental picture look for NYSE:HAE?

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

HAE gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 203 industry peers in the Health Care Equipment & Supplies industry. HAE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: HAE is growing strongly while it also seems undervalued. These ratings would make HAE suitable for value and growth and quality investing!

Our latest full fundamental report of HAE contains the most current fundamental analsysis.

Our Caviar Cruise screen will find you more ideas suited for quality investing.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.